# Natera Inc. (NTRA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $328.18, market value $47.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Natera Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 17.5×**. Each dollar of revenue is priced at 17.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 25.9×**. The shares trade at 25.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 0.2%** (5-yr avg -4.0%). Free cash flow equals 0.2% of the market value, above its five-year average of -4.0%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Operating margin: -10.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -9.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -12.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -12.8%**. Return on all capital, debt included, is -12.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -8.0%**. Each dollar of assets produces -8.0% of profit.

## Growth
- **Revenue growth (1 yr): 35.9%** (3-yr 41.1%/yr, 5-yr 42.6%/yr). Revenue grew 35.9% over the last year, against 42.6% a year compounded over five years.
- **EPS growth (1 yr): 0.7%**. Earnings per share rose 0.7%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.05**. Debt is 0.05 times equity: a conservative balance sheet.
- **Current ratio: 3.39** (quick 3.39). Current assets cover the next year's liabilities 3.39 times.
- **Altman Z-score: 43.44**. A Z-score of 43.44 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Natera Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (21 analysts). 21 analysts cover Natera Inc.; the consensus is strong_buy, with an average price target of $338.07 (+3% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 97.0%** (YTD 43.3%, 3-mo 52.4%). The shares are up 97.0% over twelve months including dividends.
- **From 52-week high: -4.4%** (108.5% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 62**. An RSI of 62 is neutral.
- **Beta (1 yr): 1.25** (volatility 48%). Beta of 1.25 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NTRA · Page: https://foliofundamentals.com/stocks/ntra

Not investment advice.